About ARTMS
ARTMS is a company based in Vancouver (Canada) founded in 2013 was acquired by Telix Pharma in March 2024. ARTMS has raised $26.58 million across 5 funding rounds from investors including GF Securities, Telix Pharmaceuticals and Innovate BC. ARTMS operates in a competitive market with competitors including NorthStar Medical Radioisotopes, Niowave, Nanovista, Ground Fluor Pharmaceuticals and ATOMIC ALCHEMY, among others.
- Headquarter Vancouver, Canada
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website artms.ca
- Social LinkedIn X
- Acquired by Telix Pharma (Mar 2024)
- Total Equity Funding$26.58M (USD)
in 5 rounds
- Latest Funding Round$300K (USD), Grant
Feb 2021
- InvestorsGF Securities
& 4 more
- Acquired byTelix Pharma
(Mar 2024)
Funding Insights of ARTMS
ARTMS has successfully raised a total of $26.58M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $300 thousand completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $26.58M
- Total Rounds 5
- Last Round Grant — $300,000
- First Round $3.27M
(Jun 2017)
- Investors Count 4
All 5 funding rounds of ARTMS with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2021 | $300,000 | Grant | – | – | |
| May 2020 | $18.82M | Series A | – | Deerfield | |
| Aug 2019 | $1.5M | Series A | – | – | – |
| Dec 2017 | $3M | Series A | – | – | |
| Jun 2017 | $3.27M | Seed | – | Quark Venture | – |
5 investors in total: 5 institutional.
Investors in ARTMS
ARTMS has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include GF Securities, Telix Pharmaceuticals and Innovate BC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Startup accelerator firm backed by the British Columbia Government | 2004 | innovatebc.ca | Vancouver, Canada | |
Healthcare ecosystem is supported through investment and innovation by Deerfield. | – | deerfield.com | New York, United States | |
Tech & Life Sciences focused early stage VC firm investing in North America | – | quarkventure.com | Vancouver, Canada | |
Provider of investment & asset management and financial services | 1991 | gf.com.cn | Guangzhou, China | |
Theranostic radiopharmaceuticals are developed for cancer imaging and therapy. | 2015 | telixpharma.com | Melbourne, Australia |
Investor details for ARTMS
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ARTMS
3 people are tracked at ARTMS (3 in leadership).
| Name | Role | Group |
|---|---|---|
Charles Conroy | CEO | Leadership |
Doug Gentilcore | Chief Executive Officer | Leadership |
Kevin Reimer | Vice President Of Global Sales And Marketing | Leadership |
Complete people profiles for ARTMS
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ARTMS
4 dated milestones of ARTMS across 11 years, from founding to its latest funding, stage changes and deals.
- Founded ARTMS is founded.
- Funding First funding round of $3.3M.
- Funding Latest funding round, Grant, of $300K.
- Exit Acquired by Telix Pharma.
Competitors of ARTMS
ARTMS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NorthStar Medical Radioisotopes, Niowave, Nanovista, Ground Fluor Pharmaceuticals and ATOMIC ALCHEMY, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| northstarnm.com | 2006 | Madison, United States | $15.09M | – | Provider of sourcing, purification, and separation technologies for the Nuclear Medicine market | |
| niowaveinc.com | 2006 | United States | $9.95M | – | Devices and radioisotopes for nuclear imaging are provided by Niowave. | |
| nanovista.ca | 2015 | Toronto, Canada | $2.3M | – | Multimodal visualization agents are developed for image-guided interventions. | |
| gfpharma.com | 2012 | Lincoln, United States | – | – | Proprietary chemistry for pharmaceutical synthesis is developed by the company. | |
| atomicalchemy.us | 2017 | Idaho Falls, United States | $150,000 | – | Limited information available | |
| cellbion.co.kr | 2010 | Seoul, South Korea | – | – | Radioisotope probes for medical imaging diagnostics are manufactured. | |
| azisotopes.org | 2017 | Bunker Hill, United States | $58.33M | – | Radiopharmaceuticals for diagnostic imaging are developed and produced. | |
| alsachim.com | 2005 | Illkirch Graffenstaden, France | – | – | Custom synthesis of stable radioisotopes & analytical services for pharmaceutical and biotech companies |
Detailed competitors of ARTMS
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ARTMS
The website of ARTMS (artms.ca) receives about 3.7K visits a month.
- Monthly visits3.7K
▼ 39.7% vs previous month
Websites whose visitors overlap most with ARTMS. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| columbuschemical.com | 100% | – | #1,988,503 | View details |
Latest news on Artms
Complete news archive for ARTMS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to ARTMS
10 companies that operate in the same segment as ARTMS (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ARTMS
ARTMS was founded in 2013 and raised its 1st funding round 4 years after it was founded.
ARTMS is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Charles Conroy is the current CEO of ARTMS.
ARTMS is a funded company, having raised a total of $26.58M across 5 funding rounds to date. The company's 1st funding round was a Seed of $3.27M, raised on Jun 2017.
ARTMS was founded in 2013 in Vancouver, Canada. The company operates in the radioisotope sector, where technologies for medical and research applications are developed. Services are extended to support radioisotope material creation by developers. The QIS system is utilized for turnkey production of purified radiometals. Focus is placed on enabling production processes within the healthcare isotope industry from a Canadian base.
ARTMS's top competitors include NorthStar Medical Radioisotopes, Niowave and ATOMIC ALCHEMY.
ARTMS has 5 investors. Key investors include GF Securities, Telix Pharmaceuticals, Innovate BC, Deerfield, and Quark Venture.
Yes. ARTMS was acquired by Telix Pharma in March 2024.